CervoMed (NASDAQ:CRVO - Get Free Report)'s stock had its "sell (d-)" rating restated by investment analysts at Weiss Ratings in a research note issued to investors on Friday,Weiss Ratings reports.
Other equities analysts have also recently issued research reports about the stock. Canaccord Genuity Group boosted their price target on shares of CervoMed from $21.00 to $27.00 and gave the stock a "buy" rating in a research note on Tuesday, July 29th. D. Boral Capital lifted their price objective on shares of CervoMed from $15.00 to $31.00 and gave the stock a "buy" rating in a report on Monday, August 18th. Zacks Research lowered shares of CervoMed from a "hold" rating to a "strong sell" rating in a research report on Monday, October 13th. Roth Capital set a $20.00 price target on CervoMed and gave the company a "buy" rating in a research report on Friday, October 17th. Finally, Chardan Capital reaffirmed a "buy" rating and set a $15.00 price target on shares of CervoMed in a research note on Monday, August 11th. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has issued a Hold rating and three have given a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of "Hold" and a consensus target price of $19.86.
Read Our Latest Stock Report on CervoMed
CervoMed Price Performance
NASDAQ CRVO traded down $0.01 during trading on Friday, reaching $7.07. The company's stock had a trading volume of 43,895 shares, compared to its average volume of 113,089. The firm has a fifty day moving average of $8.65 and a 200 day moving average of $8.37. CervoMed has a one year low of $1.80 and a one year high of $16.94.
CervoMed (NASDAQ:CRVO - Get Free Report) last issued its quarterly earnings results on Friday, August 8th. The company reported ($0.70) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.57) by ($0.13). The business had revenue of $1.76 million for the quarter, compared to the consensus estimate of $1.45 million. CervoMed had a negative net margin of 290.72% and a negative return on equity of 59.15%. As a group, equities analysts anticipate that CervoMed will post -1.88 EPS for the current fiscal year.
Institutional Investors Weigh In On CervoMed
A number of hedge funds and other institutional investors have recently modified their holdings of the stock. AWM Investment Company Inc. purchased a new stake in CervoMed during the 1st quarter valued at about $7,898,000. Jane Street Group LLC bought a new stake in CervoMed in the second quarter valued at approximately $414,000. Nuveen LLC purchased a new stake in shares of CervoMed during the first quarter valued at approximately $312,000. Citizens Financial Group Inc. RI grew its holdings in shares of CervoMed by 14.2% in the third quarter. Citizens Financial Group Inc. RI now owns 30,477 shares of the company's stock worth $247,000 after purchasing an additional 3,800 shares during the last quarter. Finally, Perigon Wealth Management LLC increased its stake in shares of CervoMed by 66.0% in the third quarter. Perigon Wealth Management LLC now owns 28,731 shares of the company's stock worth $232,000 after buying an additional 11,425 shares during the period. Institutional investors own 25.15% of the company's stock.
CervoMed Company Profile
(
Get Free Report)
CervoMed Inc, a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider CervoMed, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CervoMed wasn't on the list.
While CervoMed currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
